Added to YB: 2026-05-19
Pitch date: 2026-05-15
AUPH [bullish]
Aurinia Pharmaceuticals Inc.
+2.44%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
Market Cap
$2.0B
Pitch Price
$15.18
Price Target
24.64 (+58%)
Dividend
N/A
EV/EBITDA
10.71
P/E
7.03
EV/Sales
5.55
Sector
Biotechnology
Category
growth
DD: Aurinia Pharmaceuticals ($AUPH)
AUPH: Oral lupus nephritis std-of-care LUPKYNIS at $305-315M net sales 2026 floor provides $10-11 downside support vs $15.72 current. 40.8% Complete Renal Response vs 22.5% control in AURORA 1. rNPV $24.64 PT: LUPKYNIS peak $612M (2031), aritinercept $435M (dual BAFF/APRIL), zetomipzomib $500M (acquired Kezar). 92% gross margin, $480M cash, GAAP profitable Q1. Mid-2026 catalysts: PALIZADE Phase 2 data, aritinercept 2nd indication initiation. Patents to 2037.
Read full article (6 min)